Skip to main content
Smart Investors Daily
CA

NASDAQ · CADL

Candel Therapeutics, Inc.

Healthcare · Biotechnology

$5.81

Down-$0.39 (-6.29%)

Updated Nov 17, 2026, 2:18 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
355.76M
P/E ratio
-30.96
Dividend yield
0.00%
52-week range
$4.44 – $14.00
Volume
3.27M
Avg. volume
778.62K

Price performance · CADL

CADL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

CADL closed at $5.81 after 21 trading sessions, down 29.23% for the selected period.

Last close
$5.81
Period change
-29.23%
Period low
$5.81
Period high
$9.49
Daily close
View OHLC price history
CADL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$5.94$6.23$5.725$5.813.27M
Nov 13, 2026$5.325$6.63$5.20$6.206.62M
Nov 12, 2026$9.11$9.21$8.335$8.391.94M
Nov 11, 2026$9.53$9.54$9.18$9.221.1M
Nov 10, 2026$9.40$9.65$9.0886$9.35623.55K
Nov 9, 2026$8.99$9.84$8.65$9.491.37M
Nov 6, 2026$8.24$8.75$8.06$8.75955.02K
Nov 5, 2026$8.98$9.0087$7.92$8.041.23M
Nov 4, 2026$8.93$9.33$8.71$9.05993.82K
Nov 3, 2026$8.19$8.86$8.19$8.823.3M
Nov 2, 2026$8.35$8.61$8.011$8.12862.02K
Oct 30, 2026$8.56$8.61$8.16$8.33779.93K
Oct 29, 2026$8.72$8.93$8.5526$8.65740.96K
Oct 28, 2026$8.13$8.69$8.13$8.67663.86K
Oct 27, 2026$7.78$8.37$7.741$8.25928.46K
Oct 26, 2026$8.44$8.44$7.70$7.79849.3K
Oct 23, 2026$8.33$8.33$7.905$8.031.18M
Oct 22, 2026$8.45$8.79$8.255$8.38762.58K
Oct 21, 2026$8.65$8.82$8.35$8.371.1M
Oct 20, 2026$8.17$8.84$8.125$8.641.13M
Oct 19, 2026$8.37$8.4994$7.96$8.211.28M

Latest CADL news

The latest Smart Investors Daily articles mentioning CADL.

CADL research

Overview

Company profile and research snapshot.

Company profile

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$15.00
Implied upside
—
Analysts
14
CADL recent ratings
DateFirmRatingTarget
Nov 13, 2026HC Wainwright & Co.Buy—
Nov 13, 2026StifelBuy—
Nov 13, 2026Canaccord GenuityBuy—
Oct 22, 2026JefferiesBuy—
Sep 21, 2026B of A SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer (NSCLC), and for linoserpaturev in recurrent glioblastoma PrTK05 data show systemic cytotoxic T-cell activation following intraprostatic administration of aglatimagene in intermediate-risk localized prostate cancer, together with data consistent with transient biodistribution and shedding, supporting

Yahoo · Nov 5, 2026

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on November 3, 2026, the Compensation Committee of Candel’s Board of Directors granted Maria Ostrovsky, in connection with her employment as Candel’s General Counsel, stock options to purchase an aggregate of 315,000

Yahoo · Nov 2, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on October 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 107,600 shares of the Company's common stock, with a per

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.